NCT06258629

Brief Summary

Prognostic value of 'CD200' in hematological malignancies Hematological malignancies comprise a group of malignant clonal disorders arising from the hematopoietic tissues , including leukemia , multiple myeloma , and lymphoma , and they have a high morbidity and mortality

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2024

Shorter than P25 for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 6, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

February 14, 2024

Completed
1 day until next milestone

Study Start

First participant enrolled

February 15, 2024

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 6, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 6, 2025

Completed
Last Updated

February 14, 2024

Status Verified

February 1, 2024

Enrollment Period

12 months

First QC Date

February 6, 2024

Last Update Submit

February 13, 2024

Conditions

Hematological Malignancies

Outcome Measures

Primary Outcomes (1)

  • Level of CD200 diagnostic marker assessed by flow cytometry

    Prognostic value of CD200 in hematological malignancies

    one year

Study Arms (3)

control group

Age and sex matched healthy control individuals

Diagnostic Test: Flowcytometry on bone marrow aspiration

Case group

Available number of patients with newly diagnosed as hematological malignancy

Diagnostic Test: Flowcytometry on bone marrow aspiration

Case group after 6 months

Available number of patients with newly diagnosed as hematological malignancy after 6 months of starting treatment.

Diagnostic Test: Flowcytometry on bone marrow aspiration

Interventions

Flowcytometry on bone marrow aspirationDIAGNOSTIC_TEST

Flowcytometry on bone marrow aspiration

Case groupCase group after 6 monthscontrol group

Eligibility Criteria

Age1 Year - 60 Years
Sexall
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

* Control group of healthy individuals. * Newly diagnosed cases of hematological malignancis.

You may qualify if:

  • Newly diagnosed cases of hematological malignancis.

You may not qualify if:

  • Known cases of hematological malignancies and on treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (4)

  • Biondi A, Cazzaniga G. Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses. Hematology Am Soc Hematol Educ Program. 2013;2013:612-9. doi: 10.1182/asheducation-2013.1.612.

    PMID: 24319240BACKGROUND

  • Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci Transl Med. 2018 Apr 11;10(436):eaao3003. doi: 10.1126/scitranslmed.aao3003.

    PMID: 29643228BACKGROUND

  • Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, Valsecchi MG, Elia L, Testi AM, Mancini F, Conter V, te Kronnie G, Ferrara F, Di Raimondo F, Tedeschi A, Fioritoni G, Fabbiano F, Meloni G, Specchia G, Pizzolo G, Mandelli F, Guarini A, Basso G, Biondi A, Foa R. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013 Nov;98(11):1702-10. doi: 10.3324/haematol.2012.080432. Epub 2013 May 28.

    PMID: 23716539BACKGROUND

  • Coles SJ, Wang EC, Man S, Hills RK, Burnett AK, Tonks A, Darley RL. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia. 2011 May;25(5):792-9. doi: 10.1038/leu.2011.1. Epub 2011 Jan 28.

    PMID: 21274000BACKGROUND

MeSH Terms

Conditions

Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Central Study Contacts

Reem ya Hashim, resident

CONTACT

01285481488reem011091@med.sohag.edu.eg

sherine Ph aziz, resident

CONTACT

01227848855

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
6 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident of clinical pathology in sohag oncology center

Study Record Dates

First Submitted

February 6, 2024

First Posted

February 14, 2024

Study Start

February 15, 2024

Primary Completion

February 6, 2025

Study Completion

February 6, 2025

Last Updated

February 14, 2024

Record last verified: 2024-02